Chronic Kidney Disease: Global Burden, Risk Stratification, and Multimodal Management

Chronic Kidney Disease (CKD)—defined as kidney damage or GFR <60 mL/min/1.73m² for ≥3 months—affects ∼10% of adults worldwide. It's a progressive, often silent condition that exponentially increases cardiovascular risk and healthcare costs.

Epidemiology and Risk Stratification

Risk Factor Population Attributable Risk Mechanism
Diabetes∼40% of ESRDHyperglycemia → glomerular hyperfiltration → sclerosis
Hypertension∼25% of ESRDVascular nephrosclerosis; glomerular pressure
Age >60Prevalence 38% (60–69), 47% (≥70)Nephron loss, vascular stiffening, comorbidity accumulation
African ancestry3–4× ESRD risk (APOL1 variants)Genetic (G1/G2 variants); HIV-associated nephropathy
Male sex1.5× faster progressionHormonal, behavioral, healthcare access factors
ObesityIndependent risk factorHyperfiltration, RAAS activation, inflammation
SmokingAccelerates progressionVascular injury, oxidative stress

KDIGO Staging (GFR + Albuminuria)

Combined staging (G1–G5 × A1–A3) predicts progression and CVD risk better than GFR alone. Example: G3aA2 (GFR 45–59, ACR 30–300) has higher risk than G3aA1.

Clinical Presentation (Often Late)

  • Fatigue, anorexia, nausea, pruritus (uremic toxins)
  • Volume overload: edema, hypertension, pulmonary congestion
  • Mineral bone disorder: hyperphosphatemia, secondary HPT, vascular calcification
  • Anemia: EPO deficiency → Hb <11 g/dL
  • Metabolic acidosis: ↓ HCO₃⁻ → muscle catabolism, bone buffering
  • Cognitive impairment, neuropathy, sexual dysfunction

Evidence-Based Management Pillars

  1. Blood pressure control: Target <130/80 (KDIGO 2021); ACEi/ARB first-line (renoprotection + antiproteinuric); avoid dual RAAS blockade
  2. Glycemic control: HbA1c ∼7% (individualized); SGLT2 inhibitors (empagliflozin, dapagliflozin) — cardiorenal benefit independent of glucose
  3. SGLT2 inhibitors: Landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) — ↓ CKD progression, CVD events, death in diabetic AND non-diabetic CKD
  4. Lipid management: Statin ± ezetimibe for age ≥50; LDL target <70 mg/dL
  5. Dietary: Protein 0.8 g/kg/d (non-dialysis); sodium <2 g/d; potassium individualized; plant-dominant diet
  6. Acidosis correction: Oral bicarbonate if HCO₃⁻ <22 mmol/L
  7. Anemia management: ESA if Hb <10 g/dL; iron repletion first (TSAT >20%, ferritin >100)
  8. Mineral bone disorder: Phosphate binders, vitamin D analogs, calcimimetics per KDIGO
  9. Renal replacement planning: Pre-emptive transplant > home dialysis (PD/HHD) > in-center HD; vascular access early

Emerging Therapies

  • Non-steroidal MRA (finerenone) — FIDELIO/DIAFIGO trials
  • Endothelin antagonists (avrasentan) — glomerular protection
  • Anti-fibrotics, HIF-PH inhibitors (oral EPO)

CKD is a cardiovascular risk multiplier. Early detection (screening high-risk), SGLT2 inhibitor initiation, and multidisciplinary nephrology care alter the trajectory from inevitable decline to manageable chronic disease.

Kidney Disease - Related Articles